Moreover, the Tpm3.1/3.2 inhibitor ATM-3507 (Anisina) (29, 30) inhibits the in vitro survival, growth, and motility of the B16-F1, C8161, WM164, S462, CMTRL-100, and ST88–14 tumor cell lines, and reduces the growth of human melanoma xenografts in immunodeficient mice (30, 31, 56). This evidence concerns the gene ATM and neoplasm.